News

September 2, 2021

Board-Certified Internist and Renowned Professional Sports Team Physician, Dr. Michael S. Farber, Joins RNA Disease Diagnostics’ Advisory Board

RNA Disease Diagnostics, Inc. (RNADD), a company developing a best-in-class molecular diagnostics platform to democratize point-of-care and home-use infectious disease detection, announced today the appointment of Michael S. Farber, M.D. to its Advisory Board.

Read More
July 8, 2021

Accomplished Healthcare Industry Veteran, Richard G. Ganz, Joins RNA Disease Diagnostics’ Board of Directors

RNA Disease Diagnostics, Inc. (RNADD) announced today the appointment of Richard G. Ganz to its Board of Directors. Mr. Ganz brings more than forty years of executive experience to RNADD, having worked with businesses ranging from venture-backed startups to major international healthcare companies.

Read More
June 3, 2021

RNA Disease Diagnostics Announces University of Maryland School of Medicine Laboratory Secures FDA Registration and Approval as Development Site for Antisense COVID-19 Test

RNA Disease Diagnostics, Inc. (RNADD) announced today that the U.S. Food and Drug Administration (FDA) has registered the laboratory of Dipanjan Pan, MSc, PhD at the University of Maryland School of Medicine (UMSOM), as an approved laboratory development site for RNADD's Antisense COVID-19 molecular diagnostic test.

Read More
June 1, 2021

RNA Disease Diagnostics Further Strengthens Executive Leadership with Appointment of John W. Erickson, Jr. as President

RNA Disease Diagnostics, Inc. (RNADD) announced today the appointment of John W. Erickson, Jr. to the newly created position of President. Mr. Erickson will lead day-to-day operations, reporting directly to RNADD’s co-founder and Executive Chairman, Allan Oberman.

Read More
May 11, 2021

RNA Disease Diagnostics Announces Inaugural Joint Meeting of Expanded Board of Directors and Advisory Board

RNA Disease Diagnostics, Inc. (RNADD) announced today that it held an inaugural joint meeting of its Board of Directors and Advisory Board on May 10, 2021. The newly expanded Board of Directors and Advisory Board will work alongside the leadership team to advance RNADD's proprietary Antisense RNA diagnostic platform to prevent the transmission of infectious diseases.

Read More
May 6, 2021

RNA Disease Diagnostics Announces Publication of Stepwise Protocol for Molecular Diagnosis of COVID-19 in Esteemed Journal, Nature Protocols

RNA Disease Diagnostics, Inc. (RNADD) announced today the publication of a stepwise protocol for an RNA-extraction-free nano-amplified colorimetric test (NACT) for COVID-19 in the esteemed journal Nature Protocols. The test uses a unique dual-pronged molecular sensing approach that integrates nucleic acid (NA) amplification and plasmonic sensing to rapidly detect SARS-CoV-2 in point-of-care settings.

Read More
February 4, 2021

RNA Disease Diagnostics, Inc. Takes Exclusive License to Cutting-Edge Molecular RNA Diagnostic Platform Technology from UMB and UMBC

RNA Disease Diagnostics, Inc. (RNADD) has secured an exclusive global license to a cutting-edge sensor technology jointly owned by University of Maryland, Baltimore (UMB) and the University of Maryland, Baltimore County (UMBC).

Read More